Harcourt Jennifer L, Brown Michael P, Anderson Larry J, Tripp Ralph A
National Centers for Infectious Diseases, Division of Viral and Rickettsial Diseases, Respiratory and Enteric Virus Branch, 1600 Clifton Road NE, Mailstop G-09, Atlanta, GA 30333, USA.
Vaccine. 2003 Jun 20;21(21-22):2964-79. doi: 10.1016/s0264-410x(03)00119-1.
Respiratory syncytial virus (RSV) infection is the single most important cause of serious acute respiratory illness in children <1 year of age worldwide, and is associated with life-threatening pneumonia or bronchiolitis in the elderly. Current vaccine strategies include live, attenuated virus, subunit and DNA vaccines, however, none have been sufficiently safe, or shown to induce satisfactory long-term immunity, thus immune modulators are being considered to enhance the effectiveness of RSV vaccines. In this study, we examine CD40 ligand (CD40L) as an immune modulator to enhance the durability of DNA vaccines encoding RSV F and/or G glycoproteins in BALB/c mice. The addition of CD40L to DNA vaccines encoding the F glycoprotein enhanced virus clearance and some aspects of the immune response to RSV challenge, suggesting that CD40L may enhance the durability of RSV DNA vaccines.
呼吸道合胞病毒(RSV)感染是全球范围内1岁以下儿童严重急性呼吸道疾病的最重要单一病因,并且与老年人危及生命的肺炎或细支气管炎相关。目前的疫苗策略包括减毒活病毒、亚单位和DNA疫苗,然而,这些疫苗均未足够安全,或未显示出能诱导令人满意的长期免疫力,因此正在考虑使用免疫调节剂来提高RSV疫苗的有效性。在本研究中,我们研究了CD40配体(CD40L)作为一种免疫调节剂,以增强编码RSV F和/或G糖蛋白的DNA疫苗在BALB/c小鼠中的持久性。将CD40L添加到编码F糖蛋白的DNA疫苗中可增强病毒清除以及对RSV攻击的免疫反应的某些方面,这表明CD40L可能增强RSV DNA疫苗的持久性。